The bacillus Calmette–Guérin (BCG) vaccine, initially developed to provide protection against TB, also protects against leprosy; and the magnitude of this effect varies. Previous meta-analyses ...

BCG might be superior to sequential intravesical gemcitabine-docetaxel for reducing the risk of recurrence in patients with high-grade intermediate-risk NMIBC. Given the recent global shortage of ...

The probability of being event-free at 36 months was 82.1% (95% CI, 77.4-85.9) with sasanlimab in combination with BCG (induction and maintenance), and 74.8% (95% CI, 69.7-79.2) with BCG alone ...

With the funding, RLWRLD hopes to deepen integration with robotics and sensor companies in Asia and North America.

Adjuvant, intravesical bacillus Calmette–Guérin (BCG) therapy reduces the risk of recurrence and progression of superficial bladder cancer, but confers a considerable risk of local and systemic ...

The overall safety profile of sasanlimab in combination with BCG was generally consistent with the known profile of BCG and data reported from clinical trials with sasanlimab. The profile of ...